ZANUBRUTINIB | ZANUBRUTINIB | ATC L01EL03
ANTINEOPLASTIC BRUTON TYROSINE KINASE (BTK) COVALENT INHIBITOR TREATMENT OF MANTLE CELL LYMPHOMA (MCL) | ORAL | Cmax 1.15 MICROMOLAR Tmax 2 HOUR VD 881 LITER PPB 94 PERCENT Cl 182 LITER / HOUR HT 3 HOUR SOLUBILITY VERY SLIGHTLY SOLUBLE TO PRACTICALLY INSOLUBLE IN WATER | BRUTON TYROSINE KINASE (BTK) PDB 6J6M (CO-CRYSTAL STRUCTURE OF BTK KINASE DOMAIN WITH ZANUBRUTINIB) LIGAND CODE = BA0 (link to the list of PDB complexes) Download experimental 3D coordinates of BA0 with added hydrogens | Tyrosine-protein kinase BTK UNIPROT Q06187 BTK more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |